# Lisata Therapeutics, Inc. (LSTA)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0000320017 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000320017))
- Full page: https://inspectstocks.com/stocks/lsta
- Data as of: price 2026-09-25; newest filing used 2026-08-06; latest fiscal period ended 2026-06-30

## Grade

**C-** on the growth-and-cash rubric, 3 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Revenue growing overall | passed | $100K | $0.00 |
| Revenue growing recently | failed | $100K | $170K |
| Free cash flow positive | failed | -$12.3M |  |
| Free cash flow growing overall | passed | -$12.3M | -$21.5M |
| Free cash flow growing recently | passed | -$12.3M | -$16M |

Business quality (the + / − mark): 1 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -14,621.0% |  |
| Healthy profit margin | failed | -14,621.0% |  |
| Strong operating margin | failed | -16,427.0% |  |
| Good return on equity | failed | -98.4% |  |
| Debt under control | passed | 0.00 |  |
| Turns sales into cash | failed | -12,323.0% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $100K |
| Net income, trailing twelve months | -$14.6M |
| Free cash flow, trailing twelve months | -$12.3M |
| Net margin | -14,621.0% |
| Operating margin | -16,427.0% |
| Return on equity | -98.4% |
| Debt to equity | 0.00 |
| Diluted EPS, trailing twelve months | -$1.64 |
| Share price | $1.58 |
| Market value | $14.2M |
| Price / sales | 142.4x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/lsta)
- [Financial statements](https://inspectstocks.com/stocks/lsta/financials)
- [Competitors](https://inspectstocks.com/stocks/lsta/peers)
- [Earnings](https://inspectstocks.com/stocks/lsta/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.